skin cancer
Akoya Biosciences Licenses Early-Stage Melanoma Test From NeraCare
The exclusive license agreement builds on an existing research collaboration between the companies to develop assays for skin cancer using Akoya's immunofluorescence platform.
Castle Biosciences Q3 Revenues up 39 Percent
The company saw growth across its melanoma, squamous cell carcinoma, Barrett's esophagus, and pharmacogenomics tests.
Several new studies appear to confirm the test's potential to prevent overtreatment of melanoma patients while identifying those at high risk.
Castle Biosciences Q2 Revenues Jump 74 Percent
The firm saw particularly high volume growth for its newer tests, including assays for Barrett's esophagus and IDgenetix, its recently acquired PGx assay.
Akoya Biosciences, NeraCare Partner to Develop Melanoma Tests
The companies will develop tests for patient stratification and therapy selection for early melanoma using the PhenoImager HT platform and Immunoprint assay.
Apr 17, 2024
DermTech Receives Delisting Warning From Nasdaq
May 9, 2022
Castle Biosciences Q1 Revenues Grow 18 Percent
May 4, 2022
DermTech Posts 48 Percent Jump in Q1 Revenues
Feb 28, 2022
Castle Biosciences Q4 Revenues Grow 45 Percent
Nov 9, 2021
Dermtech Q3 Revenues Rise 122 Percent
Nov 8, 2021
Castle Biosciences Q3 Revenues Rise 54 Percent
Oct 27, 2021